The Health Technology Assessment (HTA) Council invites interested researchers to express interest and submit capsule proposals under the 2026 HTA Topics – Batch 2 Call [HTA General Track – Cycle 2 topics for Clinical, Economic and Ethical, Legal, Social, and Health Systems Impact (ELSHI) assessments; Pre-Cycle 1 topics for Economic and ELSHI Assessments] The following continue reading : CALL FOR EXPRESSION OF INTEREST: HTA Research Agenda Program [HTA Research Topics 2026 – Batch 2]
HTA Council Preliminary Recommendation on Paroxetine, Vortioxetine and Brexpiprazole for treatment of mental health conditions
As of 23 April 2026, the HTA Council has completed the evidence appraisal on the assessment of the following drugs for their respective indications, for possible government financing: The health technologies were reviewed vis-à-vis the Philippine Food and Drug Administration (FDA) marketing authorization status, clinical practice guidelines (CPGs) [local and approved by the Department of continue reading : HTA Council Preliminary Recommendation on Paroxetine, Vortioxetine and Brexpiprazole for treatment of mental health conditions
HTA Council Preliminary Recommendation on Iopromide 623.40 mg/mL and 768.86 mg/mL in 500 mL clear glass infusion bottle for use as radiocontrast media
As of 23 April 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of iopromide (1) 623.40 mg/mL (equivalent to 300 mg iodine) and (2) 768.86 mg/mL (equivalent to 370 mg iodine) in 500 mL in clear glass infusion bottle for use as radiocontrast media. The HTA Council hereby continue reading : HTA Council Preliminary Recommendation on Iopromide 623.40 mg/mL and 768.86 mg/mL in 500 mL clear glass infusion bottle for use as radiocontrast media
HTA Council Preliminary Recommendation on Pembrolizumab and Atezolizumab for Non-Small Cell Lung Cancer (NSCLC)
As of 12 March 2026, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Pembrolizumab (100 mg/4 mL [25 mg/mL] solution for IV infusion) and Atezolizumab (1200 mg/20 mL [60 mg/mL] concentrate for solution for IV infusion) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) continue reading : HTA Council Preliminary Recommendation on Pembrolizumab and Atezolizumab for Non-Small Cell Lung Cancer (NSCLC)
CALL FOR EXPRESSION OF INTEREST: 2026 Health Technology Assessment (HTA) Research Agenda [Accelerated HTA Track]
The Health Technology Assessment (HTA) Philippines invites interested researchers to to express interest and submit full proposals for accelerated HTA (aHTA) of selected topics under the 2026 Health Technology Assessment (HTA) Research Agenda [Accelerated HTA Track] The following are the health technology topics for assessments to be funded under this call for Full Proposals: aHTA Topics for Commissioning For continue reading : CALL FOR EXPRESSION OF INTEREST: 2026 Health Technology Assessment (HTA) Research Agenda [Accelerated HTA Track]